Genomic Health of Redwood City, Calif., has received US Patent No. 7,056,674, "Prediction of likelihood of cancer recurrence." The patent claims gene sets that can be expressed and used in the diagnosis and/or prognosis of cancer, particularly breast cancer, specifically with respect to disease-free survival. The patent also describes the use of archived paraffin-embedded biopsy material for assay of all markers in the set, and specifies oligonucleotide sequences that can be used for the gene sets in the test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.